Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNESCAN HIDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNESCAN HIDA.
DRAXIMAGE MDP-25 vs TECHNESCAN HIDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical